|Datasheet||Specific References||Reviews||Related Products||Protocols|
|Vector Type||Mammalian Expression Vector|
|Expression Method||Constiutive, Stable / Transient|
|Selection In Mammalian Cells||Hygromycin|
Human influenza hemagglutinin (HA) is a surface glycoprotein required for the infectivity of the human virus. The HA tag is derived from the HA-molecule corresponding to amino acids 98-106 has been extensively used as a general epitope tag in expression vectors. Many recombinant proteins have been engineered to express the HA tag, which does not appear to interfere with the bioactivity or the biodistribution of the recombinant protein. This tag facilitates the detection, isolation, and purification of the proteins.
The actual HA tag is as follows: 5' TAC CCA TAC GAT GTT CCA GAT TAC GCT 3' or 5' TAT CCA TAT GAT GTT CCA GAT TAT GCT 3' The amino acid sequence is: YPYDVPDYA.
|Human SerpinE1 ORF mammalian expression plasmid, C-GFPSpark tag||HG10296-ACG|
|Human SerpinE1 ORF mammalian expression plasmid, C-OFPSpark / RFP tag||HG10296-ACR|
|Human SerpinE1 ORF mammalian expression plasmid, C-Flag tag||HG10296-CF|
|Human SerpinE1 ORF mammalian expression plasmid, C-His tag||HG10296-CH|
|Human SerpinE1 ORF mammalian expression plasmid, C-Myc tag||HG10296-CM|
|Human SerpinE1 ORF mammalian expression plasmid, C-HA tag||HG10296-CY|
|Human SerpinE1 Gene cDNA clone plasmid||HG10296-M|
|Human SerpinE1 ORF mammalian expression plasmid, N-Flag tag||HG10296-NF|
|Human SerpinE1 ORF mammalian expression plasmid, N-His tag||HG10296-NH|
|Human SerpinE1 ORF mammalian expression plasmid, N-Myc tag||HG10296-NM|
|Human SerpinE1 ORF mammalian expression plasmid, N-HA tag||HG10296-NY|
|Human SerpinE1 natural ORF mammalian expression plasmid||HG10296-UT|
|Learn more about expression Vectors|
Plasminogen activator inhibitor 1, also known as PAI-1, Endothelial plasminogen activator inhibitor, SerpinE1 and PLANH1, is a secreted glycoprotein which belongs to the serpin family. SerpinE1 is the primary physiological inhibitor of the two plasminogen activators urokinase (uPA) and tissue plasminogen activator (tPA). Its rapid interaction with TPA may function as a major control point in the regulation of fibrinolysis. Defects in SerpinE1 are the cause of plasminogen activator inhibitor-1 deficiency (PAI-1 deficiency) which is characterized by abnormal bleeding due to SerpinE1 defect in the plasma. High concentrations of SerpinE1 have been associated with thrombophilia which is an autosomal dominant disorder in which affected individuals are prone to develop serious spontaneous thrombosis. Studies of PAI-1 have contributed significantly to the elucidation of the protease inhibitory mechanism of serpins, which is based on a metastable native state becoming stabilised by insertion of the RCL into the central beta-sheet A and formation of covalent complexes with target proteases. Greater expression of PAI-1 has been associated with increased survival of cells and resistance to apoptosis. PAI-1 appears to influence apoptosis by decreasing cell adhesion (anoikis) as well as its effect on intracellular signaling. PAI-1, in its active state, also binds to the extracellular protein vitronectin. When in complex with its target proteases, it binds with high affinity to endocytosis receptors of the low density receptor family. The mechanisms of PAI-1 overexpression during obesity are complex, and it is conceivable that several inducers are involved at the same time at several sites of synthesis. PAI-1 is also implicated in adipose tissue development. It suggests that PAI-1 inhibitors serve in the control of atherothrombosis.